With the high availability of a non-intoxicating compound, cannabidiol (CBD) has generated heightened interest in its use in the field of oncology. This review focuses on the widespread therapeutic potential of CBD with regard to enhanced wound healing, lowered toxicity profiles of chemotherapeutics, and augmented antitumorigenic effects.
This study addresses the potential influence of regular or occasional CBD usage on therapeutic outcomes in ovarian cancer patients. Additionally, as the development of chemo-resistance in ovarian cancer results in treatment failure, the potential for CBD to augment the efficacy of conventional chemotherapeutic and epigenetic drugs is a topic of significant importance. This review is focused on the widespread therapeutic potential of CBD and whether or not a synergistic role exists in combination with epigenetic and classic chemotherapy medications.
The findings from this study show that CBD may hold significant promise with regards to both monotherapy and combined treatment when used in conjunction with standard chemotherapeutics as well as with epigenetic and immunotherapy. Using CBD as an adjunct may further augment the efficacy of standard therapies, aid in the reversal of chemo-resistant disease, promote wound healing after surgery, and help alleviate toxic side effects simultaneously, resulting in an overall improved quality of life for oncology patients. Additionally with regard CBD’s perceived antiemetic, anxiolytic, and analgesic properties, understanding the potential role of CBD as an immunomodulator to help balance the immune response in order to fight cancer is an area of significant interest.
Goodbody has no association with the organisation that conducted this research and is not in a position to validate the research methods, results or conclusions of the published article. It is provided for awareness of research available that may be of interest only. Any reader should read a range of articles and research to have a balanced and informed view.